About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase 1 Trial of Oral Ixabepilone | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDPhase 1NCT00632424

Phase 1 Trial of Oral Ixabepilone

This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosin...

Lead sponsor: R-Pharm•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

R-Pharm

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Males and females, 18 or older
•Histologically or cytologically confirmed diagnosis of solid tumor malignancy
•Measurable or non-measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria
•Karnofsky Performance Status (KPS) of 70-100
•Recovered from toxicities resulting from previous therapies

Exclusion Criteria

•More than 3 prior cytotoxic regimens in the metastatic setting
•Current or recent gastrointestinal (GI) disease that would impact the absorption of study drug
•Inability to swallow whole capsules
•Inadequate hepatic and renal function
•Function exposure to any epothilone

Related studies

RECRUITINGPhase 1/2

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

NCT07060989 · Advanced Solid Tumors

RECRUITINGPhase 1

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation

RECRUITINGPhase 1

A Study of PHST001 in Advanced Solid Tumors

NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more

RECRUITINGPhase 1/2

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697 · Advanced Solid Tumors

RECRUITINGPhase 1/2

Study of CM518D1 in Patients With Advanced Solid Tumors

NCT07019779 · Advanced Solid Tumors

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 10, 2016Terms

Trial snapshot

StatusTERMINATED

PhasePHASE1

Enrollment23

Start dateMay 2008

Last updatedMar 10, 2016

Condition

Advanced Solid Tumors

Locations shown

Stanford University

Stanford, California

Georgetown University Medical Center

Washington D.C., District of Columbia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 10, 2016Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions